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Abstract 
Background: Osteoarthritis (OA) is the most common chronic condition of the joints that takes place when the 
cartilage or a low friction surface between joints breaks down which leads to pain, stiffness and swelling. The purpose 
of the present study was to evaluate the therapeutic effect of intra-articular hyaluronic acid (HA) in comparison to 
corticosteroids (CS) for knee osteoarthritis.
Methods: 140 patients with knee osteoarthritis, who were followed for 3 months, were randomized to receive intra-
articular injection of either hyaluronic acid or corticosteroid. By receiving one injection of drug during the enroll-
ment in the study, the patients were treated. With the Western Ontario and McMaster University Osteoarthritis Index 
(WOMAC), Knee injury and Osteoarthritis Outcome Score (KOOS), and the visual analog pain scale, an independent, 
blinded evaluator assessed the patients three times.
Results: The mean age of the patients in the corticosteroid group were 57 ± 1.9 years and in Hyaluronic acid group 
were 58.5 ± 8.3 years. WOMAC score represented that pain and stiffness did not improve in neither groups at any 
time points after intervention (P > 0.05). KOOS score suggested that symptoms improved after 3 months in both CS 
and HA groups. Besides, daily activity improved in both groups (P < 0.05).
Conclusions: As a conclusion, it is argued that the most important difference between the two intervention groups 
is the duration of effectiveness. HA is suggested to be superior in the duration of pain relief when compared to CS. We 
can propose that HA can be administered every 3 months intra-articular for knee joint OA. Therefore, when CS has to 
be injected every 2 months, it will be more convenient to use HA.
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Background
Osteoarthritis is a chronic progressive joint disease 
which often affects middle-age to the elderly (Lawrence 
et  al. 2008). A recent finding showed that symptomatic 
knee OA occurs in 10 % of men and 13 % of women aged 
60 years or older (Zhang and Jordan 2010). The research 
demonstrated that multifactorial etiology such as a vari-
ety of risk factors including aging, genetics, trauma, mal 
alignment, and obesity interact with one another to cause 
the mentioned disorder (Loeser 2001). Pain reduction, 
joint mobility improvement, and functional impairment 
limitation are the major objectives in OA treatment. 
Moreover, regarding the maintenance of patients’ inde-
pendence and quality of life, secondary goals have been 
taken into account for the reduction of disease progres-
sion and improvement of muscular strength (Snibbe 
and Gambardella 2005). There are various conservative 
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treatments for knee OA which provide short-term effec-
tiveness with their own advantages and disadvantages 
(McArthur et al. 2012). By using a variety of non-surgical 
treatments, such as oral analgesics, non-steroidal anti-
inflammatory drugs, or any of several types of intra-artic-
ular injections, for most patients it might prolong time 
to undergo surgery. This would be true if there could be 
any disease- modifying medication. This is why hyalu-
ronic acid (HA) and corticosteroids (CS) are of particular 
interest.
Not merely intra-articular HA injections have a benefi-
cial effect in the treatment of OA but also has some inte-
gral roles in improving joint lubrication, synovial fluid 
viscosity, normalizing hyaluronan synthesis, inhibiting 
proteoglycan degradation, exhibiting analgesic and anti-
inflammatory effects (Day et al. 2004). Additionally, it has 
a long duration of action (Dixon et  al. 1988; Dougados 
et al. 1993).
In recent decades, intra-articular injections of CS have 
been used in the treatment of OA but clinical evidences 
suggest short-term effectiveness, usually one to 4 weeks. 
Long-term treatment could promote joint destruction and 
tissue atrophy (Raynauld et al. 2003). Studies of cartilage 
damage, however, tend to recommend that changes are 
more likely due to the underlying disease than the steroid 
injection (Ayral 2001). Several clinical studies have been 
compared face to face HA and CS in knee OA (Leighton 
et al. 2014; Shimizu et al. 2010; Skwara et al. 2009). Colen 
et al. (2010), in meta-analysis study compared HA and CS 
and provided an efficacy pattern which had been changed 
by the passage of time and came into this conclusion that 
8 weeks after injection, HA had greater efficacy. Numer-
ous systematic reviews have investigated HA effects and 
other placebos (Colen et  al. 2012; Divine et  al. 2007), or 
CS and placebos (Arroll and Goodyear-Smith 2004; God-
win and Dawes 2004), however, there are a number of 
studies about HA and CS (Bannuru et al. 2009). Thus, the 
aim of the present study was to determine which treat-
ment method was more effective to compare intra-articu-
lar HA injection with CS.
Methods
Design
This was a randomized, double blind study with parallel 
groups. After approval of institutional research deputy 
and ethics committee, the patient suffering from knee 
OA were randomized to receive IA injections of 2 cc of 
high molecular weight (500,000–730,000) HA (Fidia Far-
maceutici S.p.A, Italy) or IA injections of 40 mg CS. The 
treatment consisted of one IA injections of HA or one 
injection of CS. And the follow-up visits were scheduled 
at 1, 2, and 3  months. Before inclusion, for fulfillment 
of the entry criteria, patients were evaluated. Moreover, 
qualified patients were informed about the aim and 
design of the study.
Adequate patients were randomized 1:1. A computer-
generated list of random numbers was used. The ran-
dom sequence was created through the freely accessible 
tools available at http://www.randomization.com, which 
uses the pseudo-random number generator of Wich-
mann and Hill (1982) modified by (McLeod 1985). This 
method helps to introduce several aim of interventions 
which includes a basis for the generator of random num-
ber which allows reproduction of the randomization 
model of one study when details and labels are assigned 
similarly.
At the initial visit the allocation sequence was hid-
den from the people in order to determine the patient’s 
eligibility. When the patients’ eligibility was confirmed 
by a physician, a number was presented. According to 
the randomization list, a physician was responsible for 
the patients’ assignment. Both the researcher in charge 
of evaluations at follow-up and patients’ group assign-
ment and the patients were blind. By inserting the needle 
into the suprapatellar pouch, under aseptic conditions, 
administration of the IA treatments occurred using a 
single injection, planned to be repeated at 3 months. To 
avoid any effusions, before each injection, Arthrocentesis 
was performed.
Patients selection criteria
Qualified patients included men and women from 45 to 
80  years who were suffering from knee OA for at least 
3  months, along with radiographic OA grade II–III 
(According to Kellgren and Lawrence (KL) grading scale 
(Kellegren and Lawrence 1957), who signed the informed 
agreement form for participation). Main excluded par-
ticipants for this study included a history or presence of 
trauma or surgery or cancer or malignant tumors, infec-
tions and sores on the target knee, history of vasovagal 
shock, use of NSAIDs in 2  days prior to injection, any 
receiving corticosteroids injection in the knee in the last 
6 months, pregnancy and lactation.
Instruments
Western Ontario McMaster University Osteoarthritis 
(WOMAC)
In this study, Farsi version of the WOMAC index was 
used (Nadrian et al. 2012). The index is a 24-item ques-
tionnaire divided into three subscales which meas-
ure pain (5 items, score range 0–20), stiffness (2 items, 
score range 0–8), and physical function (17 items, score 
range 0–68). The three normalized subscale values were 
summed to provide the normalized WOMAC-total 
score. In the last section of follow-up, the researcher 
asked the WOMAC questions again.
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The Knee Injury and Osteoarthritis Outcome Score (KOOS)
Having designed to evaluate the patients’ attitude on the 
knees and related problems, the KOOS is a tool specifi-
cally used for knee. The KOOS measures not only short-
term but long-term sequellae of knee injury. It contains 
42 items in 5 scored subscales including Pain, Other 
Symptoms, Function in daily living (ADL), Function 
in Sport and Recreation (Sport/Rec), and Knee-related 
Quality of Life (QOL) (Roos and Lohmander 2003).
Visual analog scale
The visual analog scale (VAS) is an instrument regularly 
used to measure pain intensity based on a 0–10 cm (Flan-
dry et al. 1991). In the present study, the researcher asked 
the patients: “Based on VAS, how much pain are you in/
experiencing?” In the follow-up sections, based on VAS, 
the researcher asks about their pain again. The measure-
ment was recorded by the orthopedic surgeon.
Statistical analysis
Data was presented as mean ± standard deviation. Com-
parison of demographic variables were done with Chi 
square test. VAS pain, WOMAC and KOOS sub scores 
was evaluated during time and simultaneously compared 
between study groups with repeated measurement of 
ANOVA. All statistical analysis were done in IBM SPSS 
19 (SPSS Inc, Chicago, IL). P value < 0.05 considered as 
significant level.
Results
In this study 69 patients at corticosteroid group with 
age of 57.0  ±  9.1  years and 71 in Hylan group with 
58.5 ± 8.3 years were participated (P = 0.322). In corti-
costeroid group 17.4 % and in Hylan group 12.7 % were 
male (P  =  0.435). Table  1 presented other character-
istics of the groups. Two groups were at same marital 
(P =  0.984), education (P =  0.984) and occupation sta-
tus (P = 708), and cigarette smoking (P = 0.984). All 140 
recruited patients complete the 3 months follow-up.
Pain (VAS)
As shown in Fig. 1, before intervention pain score in cor-
ticosteroid group was 7.15 ±  2.01 same as Hylan group 
7.52 ± 2.17 (P = 0.313). In corticosteroid group, pain at 
end of first month significantly decreased to 5.69 ± 2.33 
(P < 0.001). At the end of second month, pain increased 
to 5.90  ±  2.33 but it was significantly lower than pain 
before intervention (P  <  0.001). At end of third month, 
pain score increased to 6.56 ± 2.15 and it was not statis-
tically different with primary pain (P = 0.200). In Hylan 
group at end of first month, pain significantly decreased 
to 6.63  ±  2.03 (P  <  0.001). Unlike corticosteroid, at 
end of second month, pain continued its decreasing 
to 6.43 ±  2.01 (P  <  0.001). At end of third month, pain 
score increased to 6.70 ± 2.01 but it was also significantly 
lower than primary pain (P  =  0.020). The difference of 
pain between two groups was significant at end of first 
month (P = 0.018), but it was not significant at the end of 
second (P = 00.167) and third month (P = 0.720).
WOMAC score
Pain (P  =  0.093) and stiffness (P  =  0.712) in corticos-
teroid group along with pain (P  =  0.109) and stiffness 
(P = 0.112) in Hylan group were not statistically different 
before 3 months after intervention (Table 2). On the con-
trary, physical function problem significantly improved 
in both corticosteroid (P = 0.026) and Hylan (P = 0.043) 
groups.
KOOS score
Symptoms improved after 3 months in both corticoster-
oid (P =  0.010) and Hylan groups (P =  0.003). Besides, 
daily activity improved in both corticosteroid (P = 0.026) 
and Hylan groups (P = 0.046). On the contrary, pain did 
not decrease 3  months after intervention in both corti-
costeroid (P = 0.099) and Hylan groups (P = 0.170).
Discussion
Osteoarthritis is a chronic disabling disease with mor-
bidity and pain. Knee is a weight bearing joint frequently 
affected by degenerative processes which cause much 
Table 1 Baseline demographic information
Corticos-
teroid
Hylan P value Chi 
square
n % n %
Sex
 Male 12 17.4 9 12.7 0.435
 Female 57 82.6 62 87.3
Occupation
 Housekeeper 55 79.7 56 78.9
 Retired 2 2.9 4 5.6 0.708
 Occupied 12 17.4 11 15.5
Education
 Less than High School 
Diploma
54 78.3 53 74.6 0.615
 High School Diploma or 
More
15 21.7 18 25.4
Marital
 Live together 68 98.6 70 98.6 0.984
 Live alone 1 1.4 1 1.4
Smoking
 No 68 98.6 70 98.6 0.984
 Yes 1 1.4 1 1.4
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disabilities. There are a few diseases modifying medical 
therapies for this disease condition. While primary treat-
ment goals in knee OA include pain reduction improve-
ment and improvement of joint mobility and function. 
Decreasing the progression of disease is an important 
secondary goal. Recent meta-analysis studies have argued 
that pharmacological interventions, to treat knee OA 
with oral NSAIDS, is inferior to intra-articular injections 
(Bannuru et  al. 2015). Intra-articular injection of visco-
supplementation with hyaluronic acid (HA) is a conserv-
ative intervention which is frequently administered with 
the hope of achievement of both primary and secondary 
therapeutic goals (Strand et al 2015).
Corticosteroids are other medications used as non-
expensive pain modifying intra-articular injections (Bel-
lamy et  al. 2006), but there are no definite long-term 
benefits (Ray 2013). These two categories of intra-artic-
ular injections need to be clinically evaluated compara-
tively to assign their indications, contra-indications, 
cost-benefits and hence, to find their solid location in the 
algorithmic approach to the treatment of OA. Few stud-
ies have compared HA and CS (Bannuru et al. 2009). This 
can enrich the data regarding the use of non-surgical 
approaches to repair degenerated knee joints (Tiku and 
Sabaawy 2015). Thus, the aim of the present study was to 
determine which treatment method was more effective to 
pain alleviation and durability.
By using VAS, it was shown that both medications 
were equally effective in pain reduction in time points of 
first and second month after intervention. The effective-
ness of pain reduction was more durable in HA group 
compared to CS. This was like what previous studies 
also provide (Ray 2013). At the end of the third month, 
pain score increased after decreasing at first and sec-
ond month endpoints. At this point the score was not 
Fig. 1 Comparison of pain trend in study groups








Mean SD Mean SD
WOMAC scores
 Pain before (0–20) 13.21 3.56 13.90 4.37 0.332
 Pain after (0–20) 12.60 3.69 13.11 4.24 0.471
 Stiffness before (0–8) 4.35 2.69 4.71 2.90 0.475
 Stiffness after (0–8) 4.44 2.63 4.29 2.88 0.762
 Physical function 
before (0–68)
35.98 11.36 35.90 12.38 0.970
 Physical function after 
(0–68)
33.29 11.03 33.54 12.69 0.907
KOOS scores
 Pain before (0–100) 34.99 17.93 31.48 21.82 0.328
 Pain after (0–100) 37.95 19.19 34.74 21.61 0.383
 Symptoms before 
(0–100)
39.23 19.15 40.19 20.07 0.784
 Symptoms after 
(0–100)
43.78 17.34 46.20 20.16 0.473
 Daily activities before 
(0–100)
47.08 16.71 47.20 18.20 0.970
 Daily activities after 
(0–100)
51.04 16.21 50.67 18.67 0.867
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statistically different with the primary pain prior to inter-
vention. It could be concluded that the duration of pain 
relief effectiveness is less than 3 months. On the contrary, 
the pain score remained significantly low after 3 months. 
In other words, the durability of efficacy of HA is more 
than 3 months and significantly longer compared to CS. 
Our result confirm the findings of Leighton et  al., who 
reported the more durable effectiveness of HA compared 
to methylprednisolone (Leighton et al. 2014).
WOMAC score represented that pain and stiffness did 
not improve in neither groups at any time points after 
intervention (Table  2). However, physical function sig-
nificantly improved in both groups. To our knowledge, 
this invaluable index has not been widely used in studies 
related to intra-articular injections (Vincent et al. 2013). 
However, this index is very appropriate in comparing the 
two injection methods. Besides, using KOOS score sug-
gested that symptoms improved after 3  months in both 
corticosteroid and Hylan groups. Moreover, daily activity 
improved in both groups. This scoring system has pro-
vided a good clue to compare the clinical efficacy of each 
intervention (Peer and Lane 2013, van Meer et al. 2013).
Consequently, it is argued that the most important dif-
ference between the two interventions is the duration of 
effectiveness. Having compared to CS, HA is suggested 
to be superior in the duration of pain relief. We can 
propose that HA can be administered every 3  months 
intra-articular for knee joint OA. Therefore, it will be 
more convenient to use HA, when CS has to be injected 
every 2  months. It is probable that HA might be more 
cost-effective than CS although independent pharma-
coeconomic studies are not sufficient. Our results pre-
sent a more conservative treatment plan compared to 
the results of Abate et  al. (2015), who have suggested a 
4 months interval schedule for intra-articular injection of 
HA, while we have clearly shown that a 3 months sched-
ule is superior. In other studies, gender-related difference 
has been reported for the effect of HA. We did not find 
this difference (Leopold et al. 2003).
The superiority of our study on others is its double 
blind method. Furthermore, we did not focus only on 
pain score. This study has used several scales to clarify 
any differences between the two intra-articular injec-
tions. Future studies with more extensive follow-ups 
are demanding and will be taken into account by our 
research group.
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